CEVEC Pharmaceuticals GmbH
🏢 View company profile →10Patents
9Active
10Granted
45Portfolio score
Filing activity: Feb 12, 2003 → Apr 17, 2023 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9315773B2 | Method for the production of permanent human cell lines | Chemistry; Metallurgy | 5 | Active |
| US10081798B2 | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same | Chemistry; Metallurgy | 2 | Active |
| US7488749B2 | Therapy of diseases of the eye, the inner ear and the central nervous system | Chemistry; Metallurgy | 2 | Expired |
| US8936908B2 | Method for the production of permanent human cell lines | Chemistry; Metallurgy | 1 | Active |
| US9371512B2 | Method for the production of permanent human cell lines | Chemistry; Metallurgy | 1 | Active |
| US11685932B2 | Inducible AAV Rep genes | Chemistry; Metallurgy | 0 | Active |
| US10793839B2 | O-glycan sialylated recombinant glycoproteins | Chemistry; Metallurgy | 0 | Active |
| US12060561B2 | Use of constitutively active variants of growth factor receptors as selection markers for the generation of stable producer cell lines | Chemistry; Metallurgy | 0 | Active |
| US11193156B2 | Recombinant glycoproteins with reduced antennary fucosylation | Chemistry; Metallurgy | 0 | Active |
| US12060569B2 | Inducible AAV REP genes | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.